Organisation paid for research Program year 2025 Source: CMS Open Payments

Clinical Research Center

Neither a doctor nor a teaching hospital

Research payments

$812,306

104 payments

Through program year 2025, Clinical Research Center is reported as receiving $812,306 in research payments, across 104 payments.

By program year

7 rows
Year Kind Amount Payments
2025 Research $15,941 14
2024 Research $28,443 17
2023 Research $17,505 14
2022 Research $83,801 24
2021 Research $198,469 6
2020 Research $148,540 10
2019 Research $319,607 19

Breakdown

Who paid Research payments · program years 2019–2025
  1. Novartis Pharmaceuticals Corporation $454,323 24 payments
  2. Romark Laboratories, LC $187,114 2 payments
  3. AbbVie, Inc. $102,731 62 payments
  4. Anika Therapeutics, Inc. $49,842 7 payments
  5. Sanofi US Services Inc. $10,071 7 payments
  6. Allergan Inc. $5,000 1 payment
  7. Amgen Inc. $3,225 1 payment
Studies the money was for Research payments · program years 2019–2025
  1. A 24 Week Multicenter Double Blind Placebo Controlled Dose Ranging Study to Investigate the Efficacy and Safety of Oral Qbw251 in COPD Patients on Triple Therapy (Laba/Lama/Ics) $202,765 3 payments
  2. Efficacy and Safety of Nitazoxanide in the Treatment of Colds Due to Enterovirus/Rhinovirus Infection $137,114 1 payment
  3. A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis $91,442 57 payments
  4. A 12-Week, Multicenter, Randomized, Double-Blind, Parallel-Arm, Placebo-Controlled Study to Assess the Efficacy and Safety of Csj117, When Added to Existing Asthma Therapy in Patients ? 18 Years of Age With Severe Uncontrolled Asthma. $75,109 3 payments
  5. A Multicenter, Randomized, Double-Blind, Placebo- Controlled Phase 2B Dose-Finding Study to Investigate the Efficacy, Safety and Tolerability of Lou064 in Adult Chronic Spontaneous Urticaria Patients Who Are Inadequately Controlled By Second Generation H1 $52,435 3 payments
  6. A Phase III Randomized Double-Blind Placebo-Controlled Trial to Evaluate the Efficacy and Safety of Nitazoxanide and Nitazoxanide Plus Oseltamivir in the Treatment of Acute Uncomplicated Influenza $50,000 1 payment
  7. An Open-Label, Multicenter, Extension Study to Evaluate the Long-Term Safety and Tolerability of Lou064 in Eligible Subjects With Csu Who Have Participated in Preceding Studies With Lou064 $47,935 4 payments
  8. HyaloFast $36,572 1 payment
  9. A 12-Week Randomized, Participant-And Investigator-Blinded, Placebo-Controlled, Parallel Group Study to Explore the Efficacy, Pharmacodynamics, Safety, and Pharmacokinetics of Two Doses of Inhaled Csj117 in Adults With Chronic Obstructive Pulmonary Disease (COPD) $18,919 2 payments
  10. A 12 Week Multicenter Randomized Double Blind Placebo Controlled Study to Assess the Efficacy and Safety of Qaw039 When Added to Standard of Care Asthma Therapy in Patients With Uncontrolled Asthma $18,598 2 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record